GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.01 USD
-0.10 (-0.23%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $43.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.01 USD
-0.10 (-0.23%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $43.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
by Zacks Equity Research
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
J&J (JNJ) Gets FDA Panel Vote for Carvykti's Expanded Use
by Zacks Equity Research
J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
by Zacks Equity Research
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
by Zacks Equity Research
Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
GSK PLC Sponsored ADR (GSK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights Booz Allen Hamilton, Molson Coors Beverage, Tyson Foods, GlaxoSmithKline and Toyota Motor.
by Zacks Equity Research
Booz Allen Hamilton, Molson Coors Beverage, Tyson Foods, GlaxoSmithKline and Toyota Motor are part of the Zacks top Analyst Blog.
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
by Zacks Equity Research
Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
by Zacks Equity Research
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
Inflation Remains Sticky in February: 5 Safe Picks
by Nalak Das
We have narrowed our search to five low-beta stocks with a solid dividend yield. These are: TAP, TSN, TM, GSK and BAH.
Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study
by Zacks Equity Research
Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
by Zacks Equity Research
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
by Zacks Equity Research
Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.
Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab
by Zacks Equity Research
The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
by Zacks Equity Research
Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
Top Research Reports for Adobe, United Parcel & Deere
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), United Parcel Service, Inc. (UPS) and Deere & Company (DE).
Why Is Gilead (GILD) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex (VRTX) Down 0.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.
GSK vs. VRTX: Which Stock Is the Better Value Option?
by Zacks Equity Research
GSK vs. VRTX: Which Stock Is the Better Value Option?
Glaxo (GSK) Up 3.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.